EGFR基因突變?cè)谖赴┲械南嚓P(guān)性研究.pdf

1、石河子大學(xué)碩士學(xué)位論文EGFR基因突變?cè)谖赴┲械南嚓P(guān)性研究姓名：樊平申請(qǐng)學(xué)位級(jí)別：碩士專(zhuān)業(yè)：病理學(xué)與病理生理學(xué)指導(dǎo)教師：鄒賽英;趙海華20100501IIAbstract Objective: To detect expression of epidermal growth factor receptor(EGFR)and epidermal growth factor receptor variant (EGFRv ) Ⅲ Ⅲ p

2、rotein and mutations of EGFR gene in gastric carcinoma(GC), to characterize the important role of EGFR mutation to expression the protein, clinicopathological parameters and biological behavior in GC. .Methods: (1) EGFR

3、and EGFRvprotein expression in 105 cases of Ⅲ GC by immunohistochemistry (SP) (2)Polymerase chain reaction - single strand conformation polymorphism analysis (PCR-SSCP) method and DNA sequencing technology, expansion of

4、 105 cases of GC EGFR gene exons 18-21, based on conformational change of its gene mutation detection .(3)The relationship between EGFR and EGFRvⅢprotein expression, EGFR mutations, clinicopathological parameters and bio

5、logical behavior was analyzed by Fisher‘s exact test and χ2 test in 105 cases of GC. Results: (1) EGFR and EGFRvprotein expression in 105 cases of GC: the rate of EGFR and EGFRv Ⅲ Ⅲ protein expression was 46.67% and 35.2

6、4%, Their expression were unrelated with gender and age of gastric carcinoma(P＞0.05), but were closely related with the degree of differentiation, depth of invasion, lymph node metastasis and clinical stages(P＜0.05) and

7、their expression was correlation(P＜0.01). (2)105 cases of gastric carcinoma in two cases of detected mutations: there were 3 cases were detected of 105 cases, the rate of mutation was 2.86%; which of two cases in exon 19

8、 were 2234-2249 TGGAATTAAGAGAAGC deletion mutation; one case in exon 21 was nucleotide 2573 point mutation(2573T→G), mutant protein structure so that arginine mutation of leucine (L858R). (3) EGFR protein expression and

9、gene mutation analysis showed: one case associated with EGFR protein positive expression, while the other one was not of two cases of exon 19 in mutations; one case of exon 21 in mutation was associated with EGFR protein

10、 positive expression, which had no correlation (P> 0.05). (4) EGFR gene mutations and clinicopathological parameters analysis that: one case was differentiated adenocarcinoma for progress, accompanied by lymph node me

11、tastasis, the other was mucinous adenocarcinoma for progress, accompanied by lymph node metastasis of exon 19 in mutations; the case of exon 21 in mutation was advanced case of poorly differentiated adenocarcinoma, accom

12、panied by lymph node metastasis. EGFR gene mutations were unrelated with gender, age, degree of differentiation and clinical stage (P> 0.05), but were related with the depth of invasion and lymph node metastasis corr

13、elation (P <0.05). Conclusion: (1) EGFR and EGFRv Ⅲ is highly expressed in gastric cancer, gastric cancer occurrence and development may play a major role; its expression with age, gender, no correlation with the degr

14、ee of differentiation, depth of invasion, lymph node metastasis and clinical staging could be used as to determine prognosis of gastric cancer indicators.(2) Expression of EGFR and EGFRvⅢ had positive correlation, overex

15、pression of EGFR in gastric carcinoma may be associated with the EGFR variant Ⅲ. (3) EGFR gene mutations in gastric carcinoma organizations were not frequent events may be the occurrence and development of GC can not aff

16、ord a major role; the cases of EGFR gene mutations in gastric carcinoma may be had stronger ability of invasion and metastasis. (4) Expression of EGFR protein was unrelated with EGFR gene exon 18,19,20,21mutations, which